Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Cynthia J Girman

Showing results (1-10 of 110) with videos related to

Pageof 11
Sort By:
Journal of Comparative Effectiveness Research|October 29, 2014
From mechanism to empiricism: the evolution of heterogeneity of treatment effectsNewell E McElwee, Cynthia J Girman
Therapeutic Innovation & Regulatory Science|December 1, 2020
Evaluating the Feasibility of Electronic Health Records and Claims Data Sources for Specific Research PurposesMary E Ritchey, Cynthia J Girman
The New England Journal of Medicine|July 25, 2020
Randomization versus Real-World EvidenceAlmut G Winterstein, Cynthia J Girman, Anton Pottegård
Clinical Therapeutics|October 5, 2023
Can Weight of Evidence, Quantitative Bias, and Bounding Methods Evaluate Robustness of Real-world Evidence for Regulator and Health Technology Assessment Decisions on Medical Interventions?Emma M Rosen, Mary E Ritchey, Cynthia J Girman
Urology|May 9, 2003
Natural history of lower urinary tract symptoms in men--result of a longitudinal community-based study in JapanNaoya Masumori, Taiji Tsukamoto, Thomas Rhodes, et al.
Therapeutic Innovation & Regulatory Science|June 4, 2025
Real-World Evidence in FDA Approvals for Labeling Expansion of Small Molecules and BiologicsYung-Fang Deng, Cynthia J Girman, Mary E Ritchey
Pharmacoepidemiology and Drug Safety|April 26, 2022
Real-world data: Assessing electronic health records and medical claims data to support regulatory decision-making for drug and biological productsCynthia J Girman, Mary E Ritchey, Vincent Lo Re
Pharmacoepidemiology and Drug Safety|December 6, 2018
Considerations in characterizing real-world data relevance and quality for regulatory purposes: A commentaryCynthia J Girman, Mary E Ritchey, Wei Zhou, et al.
Pharmacoepidemiology and Drug Safety|October 17, 2012
Variable selection for propensity score models when estimating treatment effects on multiple outcomes: a simulation studyRichard Wyss, Cynthia J Girman, Robert J LoCasale, et al.
Journal of Clinical Epidemiology|May 17, 2016
Regression coefficient-based scoring system should be used to assign weights to the risk indexHemalkumar B Mehta, Vinay Mehta, Cynthia J Girman, et al.
Pageof 11

Showing results (1-10 of 110) with videos related to

Sort By:
Pageof 11
Journal of Comparative Effectiveness Research|October 29, 2014
From mechanism to empiricism: the evolution of heterogeneity of treatment effectsNewell E McElwee, Cynthia J Girman
Therapeutic Innovation & Regulatory Science|December 1, 2020
Evaluating the Feasibility of Electronic Health Records and Claims Data Sources for Specific Research PurposesMary E Ritchey, Cynthia J Girman
The New England Journal of Medicine|July 25, 2020
Randomization versus Real-World EvidenceAlmut G Winterstein, Cynthia J Girman, Anton Pottegård
Clinical Therapeutics|October 5, 2023
Can Weight of Evidence, Quantitative Bias, and Bounding Methods Evaluate Robustness of Real-world Evidence for Regulator and Health Technology Assessment Decisions on Medical Interventions?Emma M Rosen, Mary E Ritchey, Cynthia J Girman
Urology|May 9, 2003
Natural history of lower urinary tract symptoms in men--result of a longitudinal community-based study in JapanNaoya Masumori, Taiji Tsukamoto, Thomas Rhodes, et al.
Therapeutic Innovation & Regulatory Science|June 4, 2025
Real-World Evidence in FDA Approvals for Labeling Expansion of Small Molecules and BiologicsYung-Fang Deng, Cynthia J Girman, Mary E Ritchey
Pharmacoepidemiology and Drug Safety|April 26, 2022
Real-world data: Assessing electronic health records and medical claims data to support regulatory decision-making for drug and biological productsCynthia J Girman, Mary E Ritchey, Vincent Lo Re
Pharmacoepidemiology and Drug Safety|December 6, 2018
Considerations in characterizing real-world data relevance and quality for regulatory purposes: A commentaryCynthia J Girman, Mary E Ritchey, Wei Zhou, et al.
Pharmacoepidemiology and Drug Safety|October 17, 2012
Variable selection for propensity score models when estimating treatment effects on multiple outcomes: a simulation studyRichard Wyss, Cynthia J Girman, Robert J LoCasale, et al.
Journal of Clinical Epidemiology|May 17, 2016
Regression coefficient-based scoring system should be used to assign weights to the risk indexHemalkumar B Mehta, Vinay Mehta, Cynthia J Girman, et al.
Pageof 11